| 000 | 01761 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513142708.0 | ||
| 264 | 0 | _c19980513 | |
| 008 | 199805s 0 0 eng d | ||
| 022 | _a0959-8138 | ||
| 024 | 7 |
_a10.1136/bmj.316.7139.1191 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBen-Shlomo, Y | |
| 245 | 0 | 0 |
_aInvestigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cApr 1998 |
||
| 300 |
_a1191-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 |
_aBromocriptine _xadverse effects |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 | _aPersons with Disabilities |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aSelegiline _xadverse effects |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 | _aTreatment Failure |
| 700 | 1 | _aChurchyard, A | |
| 700 | 1 | _aHead, J | |
| 700 | 1 | _aHurwitz, B | |
| 700 | 1 | _aOverstall, P | |
| 700 | 1 | _aOckelford, J | |
| 700 | 1 | _aLees, A J | |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 316 _gno. 7139 _gp. 1191-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.316.7139.1191 _zAvailable from publisher's website |
| 999 |
_c9550741 _d9550741 |
||